For a study, atopic dermatitis caused significant patient distress, including itching, sleep disruption, and a reduction in health-related quality of life. Researchers looked at how once-daily oral abrocitinib 200 mg or 100 mg monotherapy affected patient-reported outcomes of disease-specific signs/symptoms and health-related quality of life in adult and adolescent patients with moderate-to-severe atopic dermatitis.
The researchers looked at data from one phase IIb (NCT02780167) and two-phase III monotherapy studies in adult and adolescent patients with moderate-to-severe atopic dermatitis (NCT03349060, JADE MONO-1; NCT03575871, JADE MONO-2). Global severity, itch, and multi-item measured that assess additional signs and symptoms of atopic dermatitis were among the patient-reported outcome evaluations. Additional patient-reported outcome measures included sadness, anxiety, exhaustion, disease-specific and overall health-related quality of life, as well as work and general productivity among employed patients.
In all, 942 patients were enrolled in this study. From the first post-baseline assessment to week 12, improvements were seen in all patient-reported outcomes, including a Patient Global Assessment (PtGA) score of 0/1 (35.5%, 19.8%, and 5.9% for 200 mg, 100 mg, and placebo, respectively), a 4-point improvement in the Night-Time Itch Scale (NTIS; 57.0%, 42.7%, and 12.7%), a change from baseline in the Patient-Oriented Eczema Measure (POEM) score (−11.4, −8.2, and −3.4), 1-point improvement in Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD; 75.2%, 65.1%, and 33.5%), Hospital Anxiety and Depression Scales (HADS) anxiety (−2.0, −1.7, and −1.0) and depression (−1.7, −1.3, and −0.1).
Adult and adolescent patients with moderate-to-severe atopic dermatitis indicated that abrocitinib monotherapy improved disease-specific signs/symptoms and health-related quality of life across various categories, supplementing clinician-reported effectiveness and safety outcomes.